<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Etty Hary Kusumastuti</style></author><author><style face="normal" font="default" size="100%">Stephanie Natasha Djuanda</style></author><author><style face="normal" font="default" size="100%">Grace Ariani</style></author><author><style face="normal" font="default" size="100%">Gondo Mastutik</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Correlation of N-Cadherin and MMP-9 Expression with Regional Nodal Metastasis in Laryngeal Squamous Cell Carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Laryngeal cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Metastasis</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">N stages</style></keyword><keyword><style  face="normal" font="default" size="100%">N-cadherin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">679-683</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; In laryngeal carcinoma, regional nodal metastasis serves as a significant prognostic factor. A special biomarker is needed to predict the status of nodal metastases. N-cadherin, a binding protein, aids in cell migration and enabling tumor cells to spread to new locations. The involvement of matrix metalloproteinase-9 (MMP-9) in metastasis includes fostering the dissemination of tumor cells from the primary tumor and enhancing tumor cell motility. &lt;strong&gt;Objective:&lt;/strong&gt; This study seeks to explore the distinctions and relationships in N-cadherin and MMP-9 expression among patients with laryngeal squamous cell carcinoma at various N stages. &lt;strong&gt;Methods:&lt;/strong&gt; Employing a cross-sectional approach, this study conducted an analytic observational investigation on formalin-fixed paraffin-embedded patients whose histopathological diagnosis is laryngeal squamous cell carcinoma in the Pathology Laboratory of Dr. Soetomo Regional Public Hospital in 2018–2021. The samples were divided into N stages based on radiological imaging from the CT scan. Immunohistochemistry examinations were performed using N-cadherin and MMP-9 antibodies and scored using the immunoreactive score (IRS), based on percentage and intensity. The differences in expression and correlation between N-cadherin and MMP-9 were analyzed using statistical tests. &lt;strong&gt;Results:&lt;/strong&gt; Statistical insignificance was observed in N-cadherin expression at various N stages (p = 0.099). There were significant differences in MMP-9 expressions at various N stages (p = 0.0006338). There was no correlation between N-cadherin and MMP-9 expression at various N stages in laryngeal squamous cell carcinoma (p = 0.0638, rs = 0.27). &lt;strong&gt;Conclusion:&lt;/strong&gt; In laryngeal squamous cell carcinoma, MMP-9 serves as a predictor for lymph node metastasis, which, if present, deteriorates the patient's prognosis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">679</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Etty Hary Kusumastuti&lt;sup&gt;1,2&lt;/sup&gt;*, Stephanie Natasha Djuanda&lt;sup&gt;1,2&lt;/sup&gt;, Grace Ariani&lt;sup&gt;1,2&lt;/sup&gt;, Gondo Mastutik&lt;sup&gt;2&lt;/sup&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Dr Soetomo Academic General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meidrin Joni</style></author><author><style face="normal" font="default" size="100%">Eryati Darwin</style></author><author><style face="normal" font="default" size="100%">Herlambang Herlambang</style></author><author><style face="normal" font="default" size="100%">Aisyah Elliyanti</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Analysis of Matrix Metalloproteinase-9 and Tissue Inhibitor Matrix Metalloproteinase-1 Levels in the Amniochorion Membrane Patients on Premature Rupture of Membranes</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Premature rupture of membranes.</style></keyword><keyword><style  face="normal" font="default" size="100%">TIMP-1</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">910-912</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; MMP-9 is essential for extracellular matrix remodeling, which affects the incidence of premature rupture of membranes. In addition, decreased and increased levels of TIMP-1, a preferential MMP-9 inhibitor, have been reported to be associated with premature rupture of membranes because it showed an imbalance in the MMP-9 or TIMP-1 levels. This study aims to analyze MMP-9 and TIMP-1 levels in amniochorion membrane patients on premature rupture of membranes. &lt;strong&gt;Methods:&lt;/strong&gt; An analytic observational study was conducted on 70 subjects. The MMP-9 and TIMP-1 levels in the amniochorion membrane were determined by ELISA. &lt;strong&gt;Results:&lt;/strong&gt; The results of this study indicate that the amniochorion membrane in the incidence of premature rupture of membranes is characterized by increased levels of MMP-9, while TIMP-1 levels do not differ between the incidence of premature rupture of membranes. &lt;strong&gt;Conclusion:&lt;/strong&gt; Based on the research that has been done, it can be concluded that there are differences in protein levels of MMP-9 but there are no differences in protein levels of TIMP-1 in premature rupture of membranes&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">910</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Meidrin Joni&lt;sup&gt;1,*&lt;/sup&gt;, Eryati Darwin&lt;sup&gt;2&lt;/sup&gt;, Herlambang Herlambang&lt;sup&gt;3&lt;/sup&gt;, Aisyah Elliyanti&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Andalas, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Histology, Faculty of Medicine, Universitas Andalas, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Universitas Jambi, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Radiology, Nuclear Medicine Division, Faculty of Medicine, Universitas Andalas, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adyan Donastin</style></author><author><style face="normal" font="default" size="100%">Muhammad Amin</style></author><author><style face="normal" font="default" size="100%">Yulistiani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanism of High Dosage Vitamin D Supplementation on The Lung Function and Quality of Life of Stable COPD Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">6MWT</style></keyword><keyword><style  face="normal" font="default" size="100%">COPD</style></keyword><keyword><style  face="normal" font="default" size="100%">FEF25-75</style></keyword><keyword><style  face="normal" font="default" size="100%">FEV1</style></keyword><keyword><style  face="normal" font="default" size="100%">FVC</style></keyword><keyword><style  face="normal" font="default" size="100%">HDAC2</style></keyword><keyword><style  face="normal" font="default" size="100%">MDA</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Nrf2</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style  face="normal" font="default" size="100%">QOL.</style></keyword><keyword><style  face="normal" font="default" size="100%">Vitamin D</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">274-278</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Oxidative stress results from the amplification mechanism of COPD, which leads to decreased lung function and the quality of life of the sufferers. Vitamin D has a function in reducing oxidative stress levels through several mechanisms, which can be revealed by analyzing several biomarkers to determine the role of vitamin D on lung function and the quality of life of stable COPD patients. &lt;strong&gt;Methods: &lt;/strong&gt;The subjects included GOLD 2 and 3 stable COPD patients who had 25(OH)D levels of &amp;lt; 32 ng/ml and were receiving bronchodilator Indacaterol maleate therapy. The biomarkers examined included Nrf2, HDAC2, MDA, MMP-9, pulmonary function tests 6MWT, and QOL. The patients in the control and treatment groups were administered with vitamin D at a dose of 1,000 and 5,000 IU, respectively, for three months.&lt;strong&gt; Results:&lt;/strong&gt; The administration of vitamin D to the patients in the control and treatment groups can significantly reduce oxidative stress, as evidenced by reduced MDA (p-value &amp;lt; 0.01) and MMP-9 levels (p-value &amp;lt; 0.01). Vitamin D affects exercise tolerance, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects the quality of life, as evidenced by 6MWT (p-value = 0.01). Vitamin D affects Nrf2 levels (p-value = 0.08) and HDAC2 (p-value = 0.01). &lt;strong&gt;Conclusion: &lt;/strong&gt;The pathway analysis through the study of the Nrf2, HDAC2, MMP-9, and MDA levels does not prove that vitamin D can prevent decreased lung function and quality of life in patients with stable COPD.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">274</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Adyan Donastin&lt;sup&gt;1&lt;/sup&gt;, Muhammad Amin&lt;sup&gt;2,*&lt;/sup&gt;, Yulistiani&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sub&gt;1&lt;/sub&gt;Doctoral-Level Medical Science Study Program, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA; Faculty of Medicine, Nahdhatul Ulama Surabaya University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Pharmacy, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Fathi Ilmawan</style></author><author><style face="normal" font="default" size="100%">Soetjipto</style></author><author><style face="normal" font="default" size="100%">M. Guritno Suryokusumo</style></author><author><style face="normal" font="default" size="100%">M. Miftahussurur</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Hyperbaric Oxygen Therapy on the Expression of FGF, MMP-9 and Occludin in the Repair of Gastric Mucosal Erosions</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">FGF</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastric mucosal erosions</style></keyword><keyword><style  face="normal" font="default" size="100%">HBOT</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Occludin.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">660-671</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;This study was conducted to evaluate the immunohistochemical (IHC) expression of fibroblast growth factor (FGF), matrix metalloproteinase-9 (MMP-9) and occludin in the repair of gastric mucosal erosions in Wistar rats was induced by administration of aspirin, one of the non-steroidal anti-inflammatory drugs (NSAIDs). These expressions are associated with changes in histopathological features. This experimental research used a posttest only control group design. The research sample was 28 male Wistar rats that met the inclusion criteria, but not met the exclusion criteria. The samples were randomly allocated into four groups. Group 1 as negative control and group 2 as positive control. Group 3 as treatment 1, which was given HBOT (hyperbaric oxygen therapy) 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Group 4 as treatment 2, which was given HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 10 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Each group was evaluated the immunohistochemical (IHC) expression of FGF, MMP-9 and occludin, using the Remmele scale index, immune reactive score (IRS). The expressions were correlated with histopathological changes, using the HAI (Histology Activity Index) method. The results show that the HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days and for 10 days, it can improve FGF (p=0.016) and occludin (p=0.021) expression significantly. The HBOT can also reduce inflammation (p=0.005), epithelial defects (p&amp;lt;0.001) and MMP-9 expression (0.042). There is a significant difference in occludin expression (p=0.034) between 5-day HBOT and 10-day HBOT. However, there was no significant difference between the 5-day HBOT and the 10-day HBOT for reduce inflammation (p=0.845), epithelial defects (p=0.469), FGF expression (0.054) and MMP-9 expression (0.470). The provision of HBOT at 2.4 ATA significantly improved gastric mucosal erosion in NSAID-induced gastric mucosal erosion Wistar rats model, by decreasing MMP-9 expression, as well as increasing FGF and occludin expression. There is a significant difference in occludin expression between 5-day HBOT and 10-day HBOT.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><accession-num><style face="normal" font="default" size="100%">25</style></accession-num><section><style face="normal" font="default" size="100%">660</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;M. Fathi Ilmawan&lt;sup&gt;1,2&lt;/sup&gt;, Soetjipto&lt;sup&gt;3,*&lt;/sup&gt;, M. Guritno Suryokusumo&lt;sup&gt;4&lt;/sup&gt;, M. Miftahussurur&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Sciences, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Hang Tuah, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Institute of Tropical Disease, Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Hyperbaric, Universitas Pembangunan Nasional, Jakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA&lt;/p&gt;
</style></auth-address></record></records></xml>